Zydus Lifesciences has ₹36-cr tax demand scrapped; ₹4-cr liability stands

The company had earlier received multiple show-cause notices from the central excise and service tax authorities regarding alleged wrongful availment of CENVAT credit on input services for the period March 2008 to June 2017. Shares of Zydus Lifesciences Ltd ended at ₹1,018.90, down by ₹16.30 or 1.57%, on the BSE today, September 25.
Zydus Lifesciences has ₹36-cr tax demand scrapped; ₹4-cr liability stands
Zydus Lifesciences has ₹36-cr tax demand scrapped; ₹4-cr liability stands
Profile Image
CNBCTV18·author
Published Sep 25, 2025   |   8:09 AM GMT-04
Share
·
Add us onAdd us on Google

Zydus Lifesciences Limited on Thursday (September 25) said the central goods and services tax (CGST) authorities have concluded proceedings on tax demands totalling ₹39.25 crore. Of this, demands worth ₹35.90 crore were dropped, while a liability of ₹3.35 crore, along with interest and penalty, was confirmed.


The company had earlier received multiple show-cause notices from the central excise and service tax authorities regarding alleged wrongful availment of CENVAT credit on input services for the period March 2008 to June 2017.


Also Read: Zydus’ Ahmedabad oncology plant gets positive USFDA compliance update


Following oral and written submissions, the authorities dropped most of the demand. However, the Commissioner of CGST, Ahmedabad, in an order dated September 19, 2025, confirmed the ₹3.35-crore demand related to CENVAT credit on sales commission paid to foreign entities, treated as business auxiliary services under Rule 14 of CENVAT Credit Rules, 2004, read with Section 11A of the Central Excise Act, 1944.


The order was communicated to the company on September 24. Zydus Lifesciences said it will challenge the order by filing an appeal and added that there is no material financial impact on its operations.


Shares of Zydus Lifesciences Ltd ended at ₹1,018.90, down by ₹16.30 or 1.57%, on the BSE today, September 25.


Also Read: Zydus Lifesciences arm launches generic drugs for cats and dogs in US

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy